[Treatment of vaginal moniliasis during pregnancy with a new biologic antifungal agent: pimaricin].
Pregnancy creates conditions which favour the development and persistence of candidiasis (moniliasis). The resultant vaginitis is often refractory to treatment. A new fungicidal antibiotic, pimaricine (Pimafucine), was studied in 91 women with vaginal moniliasis, all of whom were pregnant. Fifty-six (63%) were cured on the basis of negative cultures and 28 became symptomfree in spite of positive cultures. In this series, 94.3% benefited from treatment.
D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D000935:Antifungal Agents / Q000627:therapeutic use*; D002181:Candidiasis, Vulvovaginal / Q000188:drug therapy*; D005260:Female; D006801:Humans; D010866:Natamycin / Q000627:therapeutic use; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious
D000900:Anti-Bacterial Agents; D000935:Antifungal Agents; D010866:Natamycin
Traitement de la moniliase vaginale gravidique par un nouvel antifongique biologique: la pimaricine.